FDA Brief

Warning letters Drugs

FDA warning letter to

Taizhou Jingshang Cosmetics Technology Co., Ltd.

High riskIssued Apr 2, 2025Posted May 13, 2025Center for Drug Evaluation and Research (CDER)

FDA warns Taizhou Jingshang Cosmetics Technology over current good manufacturing practice failures in over-the-counter drugs, including missing identity tests for high-risk ingredients.

What happened

FDA inspected the facility from November 18 to 21, 2024. It found that the firm did not test incoming components for identity, accepted supplier certificates without verification, kept incomplete laboratory records with deleted gas chromatography data, and lacked an adequate quality control unit. FDA said it received no response to the inspection findings form (Form FDA 483), and the firm committed to cease all drug production at the facility.

What FDA found

  1. The firm did not test each incoming component for identity and did not verify supplier test results at appropriate intervals.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  2. The firm failed to test each shipment and lot of a high-risk component for identity using the United States Pharmacopeia (USP) limit test that detects hazardous impurities.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  3. Laboratory records were incomplete; electronic gas chromatography data was not backed up and appeared deleted, and paper records were illegible and not traceable to batches.

    21 CFR 211.194(a)
  4. The quality control unit did not ensure change control procedures were followed for drug product manufacturing.

    21 CFR 211.22(d)
  5. The quality control unit did not ensure appropriate assay test methods, procedures, or validation for in-process and finished drug products.

    21 CFR 211.160(b)
  6. The quality control unit did not ensure an adequate ongoing stability program or an annual review of drug product production.

    21 CFR 211.166(a); 21 CFR 211.180(e)

What FDA wants

Respond in writing within 15 working days with actions taken and plans to prevent recurrence. Before resuming drug manufacturing, notify FDA, and if resuming, engage a qualified consultant to evaluate operations and perform a six-system CGMP audit.

Who should pay attention

  • companies that buy OTC drugs or cosmetics from this manufacturer
  • distributors of Chinese OTC drug products
  • quality teams managing supplier qualification for high-risk ingredients

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk